Cipla has allotted 27,906 equity shares under ESOP on 15 April 2024. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,47,89,936 comprising of 80,73,94,968 equity shares of face value Rs 2 each.Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 10 May 2024.Powered by Capital Market - Live News

Net profit of Cipla rose 31.83% to Rs 1055.90 crore in the quarter ended December 2023 as against Rs 800.96 crore during the previous quarter ended December 2022. Sales rose 13.54% to Rs 6505.66 crore in the quarter ended December 2023 as against Rs 5730.08 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales6505.665730.08 14 OPM %26.8624.56 - PBDT1902.061490.17 28 PBT1668.631218.06 37 NP1055.90800.96 32 Powered by Capital Market - Live News

Cipla (EU), UK a wholly owned subsidiary of Cipla, hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma (through its subsidiary Kemwell Biopharma UK) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products for major unmet medical needs in the United States, Japan, and EU regions. Cipla (EU) will secure a 35.2% stake in the joint venture company. By capitalizing on Cipla`s leadership in product development and commercialisation and aligning with Kemwell`s expertise in biologics and Manipal`s expertise in healthcare delivery, this strategic collaboration is aimed at expediting development, manufacturing, licensing, import and export of cutting-edge Cell therapy products to cater to patients globally. Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 25 January 2024.Powered by Capital Market - Live News